|
GERN | Geron Corp |
|
|
GERN | Geron Corp |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.59 |
| Leverage | 52.64% |
| Market Cap | $ 1.4B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -138.7m |
| Margin | -203.46% |
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.